Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Apr;17(2):118-21.
doi: 10.1007/s10286-007-0396-1. Epub 2007 Mar 2.

Cardiac sympathetic denervation preceding motor signs in Parkinson disease

Affiliations
Case Reports

Cardiac sympathetic denervation preceding motor signs in Parkinson disease

David S Goldstein et al. Clin Auton Res. 2007 Apr.

Abstract

There is substantial interest in identifying biomarkers to detect early Parkinson disease (PD). Cardiac noradrenergic denervation and attenuated baroreflex-cardiovagal function occur in de novo PD, but whether these abnormalities can precede PD has been unknown. Here we report the case of a patient who had profoundly decreased left ventricular myocardial 6-[(18)F]fluorodopamine-derived radioactivity and low baroreflex-cardiovagal gain, 4 years before the onset of symptoms and signs of PD. The results lead us to hypothesize that cardiac noradrenergic denervation and decreased baroreflex-cardiovagal function may occur early in the pathogenesis of PD.

PubMed Disclaimer

Conflict of interest statement

No author conflicts of interest were reported in the original publication of this article.

Figures

FIGURE 1
FIGURE 1
Thoracic 6-[18F]fluorodopamine (18FDA) and 13N-ammonia (13NH3) images in July 2001 and November 2005. Note absence of left ventricular myocardial 6-[18F]fluorodopamine-derived radioactivity at both times, indicating cardiac sympathetic denervation. Myocardial perfusion, as indicated by 13NH3-derived radioactivity, was normal.
FIGURE 2
FIGURE 2
Beat-to-beat heart rate and blood pressure responses to the Valsalva maneuver (12-second duration, 30 mm Hg) in July 2001 and November 2005. In the latter recording, note progressive decline in blood pressure during Phase II, smaller pressure overshoot, and delayed return of pressure toward baseline in Phase IV, consistent with worsening baroreflex-sympathoneural function. Heart rate responses during and after the maneuver were also smaller in 2005 than in 2001, despite larger changes in blood pressure, consistent with worsening baroreflex-cardiovagal function.
FIGURE 3
FIGURE 3
Individual values for septal myocardial 6-[18F]fluorodopamine-derived radioactivity, in normal control subjects (white circles), patients with Parkinson disease without sympathetic neurocirculatory failure (PD no SNF, green circles), patients with Parkinson disease and sympathetic neurocirculatory failure (PD + SNF, blue circles), and the case reported here (large green circle). Dashed line shows the normal mean value and light green shaded area 2 standard deviations from the normal mean. Note markedly decreased 6-[18F]fluorodopamine-derived radioactivity in the current case.

References

    1. Bonuccelli U, Lucetti C, Del Dotto P, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol. 2003;60:1400–1404. - PubMed
    1. Bouhaddi M, Vuillier F, Fortrat JO, et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: involvement of L-dopa therapy. Auton Neurosci. 2004;116:30–38. - PubMed
    1. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett. 2006;396:67–72. - PubMed
    1. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110:517–536. - PubMed
    1. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res. 2001;11:351–355. - PubMed

Publication types